Home » IMMTECH RECEIVES EXPANDED FUNDING COMMITMENT TO DEVELOP PAFURAMIDINE MALEATE
IMMTECH RECEIVES EXPANDED FUNDING COMMITMENT TO DEVELOP PAFURAMIDINE MALEATE
Immtech Pharmaceuticals, Inc. announced today that it has entered agreements with the University of North Carolina Chapel Hill (UNC-Chapel Hill) to provide expanded funding and support for Immtech's development of its oral drug candidate, pafuramidine maleate (DB289), to treat African sleeping sickness (trypanosomiasis). PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/05-23-2006/0004367171&EDATE=)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May